223 related articles for article (PubMed ID: 32480317)
21. Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators.
Di Leva FS; Di Marino D; Limongelli V
Handb Exp Pharmacol; 2019; 256():111-136. PubMed ID: 31161298
[TBL] [Abstract][Full Text] [Related]
22. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
23. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
Fiorucci S; Distrutti E
Pharmacol Res; 2016 Sep; 111():749-756. PubMed ID: 27475883
[TBL] [Abstract][Full Text] [Related]
24. Bile acid receptors in non-alcoholic fatty liver disease.
Li Y; Jadhav K; Zhang Y
Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
[TBL] [Abstract][Full Text] [Related]
25. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
26. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
27. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.
Sepe V; Distrutti E; Limongelli V; Fiorucci S; Zampella A
Future Med Chem; 2015; 7(9):1109-35. PubMed ID: 26132522
[TBL] [Abstract][Full Text] [Related]
28. Developments in bile salt based therapies: A critical overview.
Donkers JM; Roscam Abbing RLP; van de Graaf SFJ
Biochem Pharmacol; 2019 Mar; 161():1-13. PubMed ID: 30582898
[TBL] [Abstract][Full Text] [Related]
29. Bile Acids Elevated in Chronic Periaortitis Could Activate Farnesoid-X-Receptor to Suppress IL-6 Production by Macrophages.
Cao S; Meng X; Li Y; Sun L; Jiang L; Xuan H; Chen X
Front Immunol; 2021; 12():632864. PubMed ID: 33968024
[TBL] [Abstract][Full Text] [Related]
30. Role of Bile Acids in Metabolic Control.
Molinaro A; Wahlström A; Marschall HU
Trends Endocrinol Metab; 2018 Jan; 29(1):31-41. PubMed ID: 29195686
[TBL] [Abstract][Full Text] [Related]
31. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
32. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
[TBL] [Abstract][Full Text] [Related]
33. Bile acids and their receptors in metabolic disorders.
Fiorucci S; Distrutti E; Carino A; Zampella A; Biagioli M
Prog Lipid Res; 2021 Apr; 82():101094. PubMed ID: 33636214
[TBL] [Abstract][Full Text] [Related]
34. Counter-regulatory role of bile acid activated receptors in immunity and inflammation.
Fiorucci S; Cipriani S; Mencarelli A; Renga B; Distrutti E; Baldelli F
Curr Mol Med; 2010 Aug; 10(6):579-95. PubMed ID: 20642438
[TBL] [Abstract][Full Text] [Related]
35. Interactions between bile salts, gut microbiota, and hepatic innate immunity.
Schubert K; Olde Damink SWM; von Bergen M; Schaap FG
Immunol Rev; 2017 Sep; 279(1):23-35. PubMed ID: 28856736
[TBL] [Abstract][Full Text] [Related]
36. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
37. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.
McMahan RH; Wang XX; Cheng LL; Krisko T; Smith M; El Kasmi K; Pruzanski M; Adorini L; Golden-Mason L; Levi M; Rosen HR
J Biol Chem; 2013 Apr; 288(17):11761-70. PubMed ID: 23460643
[TBL] [Abstract][Full Text] [Related]
38. Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases.
Xu Y
J Med Chem; 2016 Jul; 59(14):6553-79. PubMed ID: 26878262
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
40. The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy.
Carino A; Marchianò S; Biagioli M; Scarpelli P; Bordoni M; Di Giorgio C; Roselli R; Fiorucci C; Monti MC; Distrutti E; Zampella A; Fiorucci S
FASEB J; 2021 Jan; 35(1):e21271. PubMed ID: 33368684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
